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ABSTRACT
Few analyses of antiresorptive (AR) treatment trials relate short-term changes in bone turnover markers (BTMs) to subsequent fracture
reduction seeking to estimate the proportion of treatment effect explained (PTE) by BTMs. Pooling such information would be useful
to assess new ARs or novel dosing regimens. In the Foundation for the National Institutes of Health (FNIH) Bone Quality project, we ana-
lyzed individual-level data from up to 62,000 participants enrolled in 12 bisphosphonate (BP) and four selective estrogen receptor mod-
ulator (SERM) placebo-controlled fracture endpoint trials. Using BTM results for two bone formation markers (bone-specific alkaline
phosphatase [bone ALP] and pro-collagen I N-propeptide [PINP]) and one bone resorption marker (C-terminal telopeptide of type I col-
lagen [CTX]) and incident fracture outcome data, we estimated the PTE using two different models. Separate analyses were performed
for incident morphometric vertebral, nonvertebral, and hip fractures over 1 to 5 years of follow-up. For vertebral fracture, the results
showed that changes in all three BTMs at 6 months explained a large proportion of the treatment effect of ARs (57 to >100%), but not
for and non-vertebral or hip fracture. We conclude that short-term AR treatment-related changes in bone ALP, PINP, and CTX account
for a large proportion of the treatment effect for vertebral fracture. Change in BTMs is a useful surrogate marker to study the anti-fracture
efficacy of new AR compounds or novel dosing regiments with approved AR drugs. © 2020 The Authors. Journal of Bone and Mineral
Research published by American Society for Bone and Mineral Research.
KEY WORDS: BIOCHEMICAL MARKERS OF BONE TURNOVER; BONE MODELING AND REMODELING; DISEASES AND DISORDERS OF/RELATED TO BONE;
EPIDEMIOLOGY; OSTEOPOROSIS
Introduction
B one turnover markers (BTMs) decrease in response to antire-sorptive (AR) treatments, and the greater the decrease the
greater the apparent reduction in fracture risk, especially vertebral
fracture.(1) Guidelines published by International Osteoporosis
Foundation (IOF) expert workinggroups proposed that BTMmight
be useful in clinical practice as an indication of failure to respond(2)
to oral bisphosphonates, especially as a result of poor adher-
ence.(3) These guidelines propose that a decrease beyond the
BTM-specific least significant change (LSC), which corresponds to
25% to 30% reductions for serum C-terminal telopeptide of type
I collagen (sCTX) and pro-collagen I N-propeptide (PINP), is
desirable.
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In treatment trials for osteoporosis medications, BTMs are
potential surrogate markers for fracture risk reduction. The Food
and Drug Administration (FDA) specifies two types of studies in
order to evaluate a surrogate marker for qualification.(4) The first
approach is a study-level meta-regression analysis, and we have
completed such an analysis for BTMs.(1) The other approach, uti-
lized in this analysis, is an individual-level analysis estimating the
proportion of treatment effect explained (PTE) by BTMs.
PTEs have been reported in single randomized controlled tri-
als of antiresorptive drugs including risedronate,(5,6) zoledronic
acid,(7) raloxifene,(8) and bazedoxifene.(9) These studies were
mostly concerned with vertebral fractures, and the point esti-
mates for PTE ranged from 14% to 67%; the one study of nonver-
tebral fractures reported a PTE of 54% to 77%.(5) There have been
no studies of hip fracture. Several BTMs have been evaluated,
including those that reflect bone resorption (urine and serum
C-telopeptide [CTX] and urine N-telopeptide of collagen [NTX])
and bone formation (bone alkaline phosphatase [ALP], procolla-
gen I N-propeptide [PINP], and osteocalcin [OC]).
The methods used for calculating PTE have differed by study
with some using an approach based on the comparison of treat-
ment effects before and after adjustment for the surrogate,(10)
and others using an approach combining treatment effects on
the surrogate and fracture, as well as the surrogate on frac-
ture.(11) These different approaches may have resulted in differ-
ent estimates for PTE.
The aim of the present study was to systematically collect
individual-level data from existing placebo-controlled trials of
AR agents and to estimate PTE for three fracture types (vertebral,
nonvertebral, hip) using three BTMs (CTX, PINP, bone ALP). We
planned to calculate PTE using both previously described
methods (Freedman and colleagues(10) and Li and col-
leagues(11)). We estimated the BTM level month by month.(12)
We also aimed to describe the relationship between change in
BTM and fracture risk on treatment or placebo from this individ-
ual patient level study to relate the prior estimates of LSC and the
mean reduction in fracture risk with antiresorptive drugs.
We faced a challenge in that generally BTMs were only mea-
sured on a subset of patients in clinical trials. We addressed this
by using the total alkaline phosphatase level to impute missing
values. We report the PTE results with and without imputation.
We included pure antiresorptive agents (hence, we excluded
odanacatib) and did not have access to BTM data on
denosumab.
Materials and Methods
This analysis was part of the Foundation of the National Institutes
of Health Bone Quality project, which is a public-private partner-
ship with the aim of studying fracture surrogates, including bone
mineral density (BMD) by dual-energy X-ray absorptiometry
(DXA) and quantitative computed tomography (QCT) as well as
BTMs. We searched through published literature for placebo-
controlled trials of AR medication as we described previously.(1)
The list of studies includesmost osteoporosis medication trials
(Table 1).(13–28) We used a standard data template. We took a
standard approach to the definition of fractures. The assays for
serum CTX, PINP, and bone ALP are described in Table 2. We
did not include results from OC, urinary NTX, or urinary CTX
because these are not used routinely in clinical practice now.
Baseline and follow-up total ALP was measured by auto-
analyzer technique and the results were correlated with bone
ALP, PINP, and CTX with correlations between 0.55 to 0.77, allow-
ing imputation for patients with missing BTM results (for all
results, see Tables).
Statistical approach
The three-stage approach we used to estimating PTE is given in
Supplemental Materials andMethods. The key points to note are:
(i) we used all the BTMmeasurements available to fit a smoothed
trajectory for each individual; (ii) when BTMmeasurements were
not available, we imputed the results from the measured level of
ALP; (iii) we then adjusted the effect of treatment on fracture risk
for the estimated change in BTMs at 6 months and calculated
PTE using the methods of Freedman and colleagues(10) or Li
and colleagues.(11)
We show the results as graphical summaries showing fracture
risk, evaluated at mean values of other covariates, plotted
against the 1st to 99th percentile of expected percent change
in BTMs in each group. The slope of each line reflects the effect
of BTM change on fracture risk, and the vertical offset between
lines for active and placebo reflects the direct effect of treatment
not mediated by change in the BTMs.
Results
We included 13 AR trials (n = 53,974) that reported 3673 incident
vertebral fracture and 15 AR trials (n = 62,064) that reported 5523
nonvertebral and 717 hip fractures (Table 1).
The baseline BTMs differed by study. For example, the range
of baseline results for CTX was 0.24 to 0.54 ng/mL. The change
in BTMs differed by drug. For example, mean percent decrease
between groups in CTX ranging from 18% (raloxifene) to 41%
(zoledronic acid) (Table 2).
Change in BTMs explains much of the reduction in vertebral
fracture (Table 3). Using the Freedman method, the PTEs varied
from 82% to 113% for vertebral fracture. None of the PTEs for
nonvertebral or hip fracture were statistically significant. Using
the Li method, the PTEs varied from 85% to 109% for vertebral
fracture. None of the PTEs for hip fracture and only one of the
PTE for nonvertebral fracture (bone ALP) were statistically
significant.
We recognized that we might obtain different results if we
just analyzed those subjects with BTMs measured directly
and not subjects with all imputed data. Thus, we repeated the
PTE estimates with just those patients with two or more
measurements of BTMs and found high estimates for PTE
(Table 3), but the confidence intervals (CI) were much wider than
for the original results (Table 3) and several of the estimates
exceeded 100%.
The different BTMs differed by the percent change in
response to active compared with placebo. These mean differ-
ences were 17% reduction for bone ALP, 31% for PINP, and
32% for CTX. The associated reductions in vertebral fracture risk
were about 41% (95% CI 37% to 45%).
Finally, we examined the relationship between 6-month
change in BTMs and vertebral fracture, and this shows that the
greater the reduction in BTMs, the lower the risk of fracture
(Fig. 1). The slopes and intercepts of the fitted lines were similar
for placebo and active treatment.
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Discussion
For AR treatments, BTMs explain a large proportion of the verte-
bral fracture benefit. The point estimates for vertebral fracture
were close to 100%, suggesting that potentially a large propor-
tion of treatment-related fracture risk reduction can be explained
by the decrease in BTMs in populations of women with osteopo-
rosis. These estimates are higher than most prior analyses, and
this may be attributable to the strength of our novel statistical
methodology. BTMs can be variable over time, but this can be
addressed by fitting smoothing models to the BTM changes.
The PTEs we report are higher than reported for the percent
treatment effect explained by LDL cholesterol for subsequent
coronary heart disease events of 52%,(29) and yet this marker is
commonly used for the registration study of cardiovascular
drugs.(30)
The estimate of PTE varied by fracture type. For example, the
PTE estimates were lower for nonvertebral and hip fracture and
mostly were not statistically significant. For hip fracture, this
may be related to number of fracture events as there were
5523 nonvertebral and 717 hip fractures, resulting in a ratio of
8:1. The 95% CI for all BTM are quite wide, and this may relate
to the variability of BTM over time.
For vertebral fracture, the greater the reduction in BTM, the
greater the reduction in the risk of fracture. This relationship
appears to be linear and the line describing placebo similar inter-
cept and slope to the line describing the AR drug, consistent with
a PTE estimate close to 100%.
Table 1. Characteristics of Placebo (PBO)-Controlled Fracture Endpoint Trials
Study name
(year
conducted) Study drug N
Age (years,
mean)/sex (%
women)
Mean
follow-up
(months)
Baseline femoral
neck T-
score (mean)
Prevalent vertebral
fracture at
baseline (%)
Fracture outcomes
vertebral/non-spine/
hip (N)
ALN Phase 3(13)
(1995)
Alendronate 994 63.5/100 32.5 −2.15 23.4 Activea: −/35/1 PBO:
−/33/3
FIT Vertebral
Fracture(14)
(1996)
Alendronate 2027 70.3/100 35.0 −2.44 100 Active: 78/109/11 PBO:
145/136/22
FIT Clinical
Fracture(15)
(1998)
Alendronate 4432 67.1/100 51.2 −2.21 0 Active: 43/234/18 PBO:
78/260/23
FOSIT(16) (1999) Alendronate 1908 62.7/100 11.4 −1.97 – Active: −/16/2 PBO:
−/36/2
Men’s Study(17)
(2000)
Alendronate 241 62.7/0 22.4 −2.15 50.2 Active: 4/−/− PBO:
7/−/−
Bone(18) (2004) Ibandronate
(oral)
2929 68.7/100 29.9 −2.10 93.6 Activea: 87/158/17
PBO: 80/71/4
IBAN IV(19)
(2004)
Ibandronate
(iv)
2860 67.0/100 34.0 −2.14 98.4 Activea: 172/159/13
PBO: 102/84/13
HIP(20) (2001) Risedronate 9331 78.0/100 24.9 −2.75 31.0 Activea: 298/601/123
PBO: 199/312/82
VERT-North
America(21)
(1999)
Risedronate 1628 68.4/100 27.8 −2.21 78.1 Active: 77/68/9 PBO:
103/89/6
VERT-Multi-
national(22)
(2000)
Risedronate 814 70.8/100 28.7 −2.40 94.1 Active: 63/47/8 PBO:
103/53/9
HORIZON
2301(23)
(2007)
Zoledronic
acid (iv)
7736 73.1/100 33.9 −2.71 63.2 Active: 138/292/52
PBO: 397/387/88
HORIZON
2310(24)
(2007)
Zoledronic
acid (iv)
2127 74.5/76.1 23.6 −2.39 – Active: −−/79/23 PBO:
−−/107/33
Generations(25)
(2010)
Arzoxifeneb 9354 67.4/100 49.3 −1.87 15.2 Active: 110/334/20
PBO: 184/353/26
BZA Phase 3(26)
(2008)
Bazedoxifeneb 5643 66.4/100 28.7 −1.82 56.1 Activea: 79/165/13
PBO: 62/93/5
PEARL(27)
(2010)
Lasofoxifeneb 8556 67.4/100 54.9 −2.19 28.2 Activea: 345/479/55
PBO: 262/281/35
MORE(28) (1999) Raloxifeneb 7705 66.0/100 31.8 −2.30 37.3 Activea: 272/437/40
PBO: 231/240/18
aActive treatment group combines multiple dosages for study reporting more than one dose.
bSERM.
Dashes indicate that no data were available.
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Table 2. Median Expected Total ALP and BTM Baseline (BL) and % Expected Change at 6 Months in Fracture Endpoint Trials
Total ALP Bone ALP PINP CTX
Study name Study drug BL (IU/L)
% change
BL (ng/mL or IU/L)
% change
BL (ng/mL)
% change
BL (ng/mL)
% change
Active PBO Active PBO Active PBO Active PBO
Overall −12.1 −3.1 −21.4 −7.3 −39.1 −9.4 −48.0 −12.6
ALN Phase 3 (2000) Alendronate 51.7 −10.7 0.8 15.1 (1) −29.4 −5.2 38.4 −41.6 −8.7 0.24 −50.0 −23.7
FIT Vertebral Fracture (2004) Alendronate 83.4 −9.2 −0.8 13.3 (1) −22.1 −8.6 47.0 (5) −39.7 −10.2 0.28 (7) −48.0 −26.1
FIT Clinical Fracture (2004) Alendronate 83.3 −9.7 −1.3 13.0 (1) −21.3 −6.3 48.4 (5) −40.3 −9.9 0.30 (7) −48.9 −24.9
FOSIT (1999) Alendronate 124.0 −19.3 −2.9 11.5 (1) −40.6 −8.9 57.5 −42.8 −10.2 0.36 −51.4 −25.0
Men’s Study (2000) Alendronate 109.7 −7.8 −0.8 11.6 (1) −19.8 −2.6 55.0 −39.7 −9.4 0.34 −48.6 −24.3
Bone (2004) Ibandronate (oral) 71.2 −12.0 −5.8 37.7 (2) −24.0 −6.5 44.6 −41.7 −11.7 0.28 −50.1 −26.2
IBAN IV (2004), CSR Ibandronate (iv) 67.4 −3.4 0.0 45.6 (2) −16.2 −5.3 43.6 −38.8 −9.1 0.27 −47.8 −24.0
HIP (2001) Risedronate 86.0 −11.1 −4.7 11.8 (1) −29.6 −10.1 45.7 (5) −49.3 −15.3 0.29 −49.5 −25.6
VERT-North America (1999, 2003) Risedronate 76.2 −11.6 −4.2 13.0 (1) −34.0 −12.6 46.4 −41.4 −10.9 0.29 −49.9 −25.5
VERT-Multi-national (2000, 2003) Risedronate 75.4 −12.7 −3.5 12.6 (1) −34.4 −7.5 45.9 −41.8 −10.6 0.28 −50.2 −25.3
HORIZON 2301 (2009) Zoledronic acid (iv) 76.5 −12.4 −3.4 13.1 (3) −20.7 −2.3 48.7 (6) −39.8 −5.6 0.30 (7) −44.3 −3.1
HORIZON 2310 Zoledronic acid (iv) 104.6 −17.2 −11.8 15.2 −23.7 −8.5 51.6 −42.3 −13.6 0.32 −50.9 −27.9
Generations (2010) Arzoxifenea 81.3 −17.5 −1.1 16.6 −21.3 −7.3 47.9 (5) −40.1 −10.3 0.54 (7) −48.7 −8.4
BZA Phase 3 (2008) Bazedoxifenea 76.3 −11.1 −5.5 16.2 −19.3 −8.8 43.5 −24.3 −5.5 0.45 (7) −50.4 −30.2
PEARL (2012) Lasofoxifenea 90.5 −18.2 −4.6 20.4 (4) −15.9 −2.1 40.7 (6) −28.3 −2.7 0.32 (7) −26.5 −3.2
MORE (2006) Raloxifenea 73.2 −11.9 −2.7 14.8 (1) −22.0 −10.5 50.9 (5) −23.1 −6.4 0.38 −28.1 −10.4
BTM = bone turnover marker; PBO = placebo; CSR = case study report.
Italics indicate bone turnover markers were not measured in specific study but imputed.
The references relate to the description of the BTM assays and the numbers in parentheses describe the assay method: Bone ALP, (1) Ostase Tandem IRMA (ng/mL), (2) Wheat germ lectin precipitation (IU/L), (3)
Beckman autoanalyzer (ng/mL), (4) Alkphase B ELISA (IU/L). PINP, (5) RIA (Orion) (ng/mL), (6) automated immunoassay analyzer (Roche Elecsys) (ng/mL). CTX, (7) CrossLaps ELISA (Nordic Bioscience).
aSERM.
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Table 3.Odds Ratio/Hazard Ratio (95% CI) for Overall Treatment Effect on Fracture and Percent of Treatment Effect (95% CI) Explained by 6-Month Change in BTM, Using Freedman and Li
Methods
Bone ALP PINP sCTX
OR/HR
PTE
OR/HR
PTE
OR/HR
PTE
Freedman Li Freedman Li Freedman Li
All participants
Vertebral
(n = 53,974)
0.58 (0.54, 0.62)
p < 0.0005
89% (48, 130%)
p < 0.0005
91% (58, 124%)
p < 0.0005
0.58 (0.54, 0.62)
p < 0.0005
82% (37, 127%)
p < 0.0005
85% (47, 123%)
p < 0.0005
0.59 (0.55, 0.64)
p < 0.0005
113% (70, 157%)
p < 0.0005
109% (81, 137%)
p < 0.0005
Nonvertebral
(n = 62,064)
0.88 (0.84, 0.93)
p < 0.0005
94% (−2, 191%)
p = 0.06
95% (13, 178%)
p = 0.024
0.88 (0.84, 0.93)
p < 0.0005
59% (−42, 161%)
p = 0.25
62% (−35, 158%)
p = 0.21
0.89 (0.84, 0.94)
p < 0.0005
57% (−34, 147%)
p = 0.22
60% (−27, 148%)
p = 0.18
Hip (n = 62,064) 0.78 (0.67, 0.90)
p = 0.001
−26% (−162, 109%)
p = 0.70
−31% (−191, 129%)
p = 0.70
0.78 (0.67, 0.90)
p = 0.001
36% (−109, 182%)
p = 0.62
38% (−111, 188%)
p = 0.62
0.81 (0.70, 0.95)
p = 0.008
−6% (−151, 138%)
p = 0.93
−7% (−182, 167%)
p = 0.93
Participants with BTM measurements
Vertebral (n = 10,
476–13,561)
0.59 (0.52, 0.68)
p < 0.0005
108% (25, 191%)
p = 0.01
106% (46, 167%)
p = 0.001
0.55 (0.47, 0.64)
p < 0.0005
154% (70, 238%)
p < 0.0005
130% (92, 169%)
p < 0.0005
0.58 (0.49, 0.68)
p < 0.0005
139% (54, 223%)
p = 0.001
124% (79, 170%)
p < 0.0005
Nonvertebral
(n =
11,093–16,798)
0.87 (0.79, 0.96)
p = 0.006
99% (−48, 246%)
p = 0.19
99% (−14, 212%)
p = 0.09
0.87 (0.78, 0.98)
p = 0.02
103% (−95, 300%)
p = 0.31
102% (−58, 262%)
p = 0.21
0.85 (0.76, 0.95)
p = 0.006
7% (−103, 116%)
p = 0.90
8% (−122, 138%)
p = 0.91
Hip (n = 11,093–
16,797)
0.87 (0.63, 1.19)
p = 0.37
−201% (−812, 411%)
p = 0.52
−430% (−2416, 1555%)
p = 0.67
0.70 (0.49, 1.00)
p = 0.05
50% (−145, 245%)
p = 0.62
57% (−150, 263%)
p = 0.59
0.65 (0.44, 0.96)
p = 0.03
−25% (−168, 118%)
p = 0.73
−37% (−273, 200%)
p = 0.76
CI = confidence interval; OR= odds ratio; HR = hazard ratio; PTE = proportion of treatment effect explained; BTM = bone turnover marker.
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Themain purpose of our analysis is to evaluate BTMs as poten-
tial surrogate markers for fracture for future trials and different
analyses would be relevant to assessing how this information
might be relevant to clinical practice. Nonetheless, our results
might further inform the interpretation of BTM when used in
clinical practice. First, it is important to know that the change
in BTMs is strongly associated with the reduction in the risk of
vertebral fracture. Second, a 25% to 30% decrease in CTX or PINP,
corresponding to the least significant change, is a threshold
sometimes used in clinical practice to define an adequate
response to antiresorptive.(2) We have shown that this value,
for grouped studies, is associated with about a 40% reduction
in vertebral fracture. This additional information provides insight
into the magnitude of vertebral fracture risk reduction associ-
ated with this level of change in BTM. Also, this relationship
between fracture risk reduction and change in BTM was similar
to our published study-level meta-regression. Treatment that
reduces PINP by 30% would be expected to reduce vertebral
fracture by 42% according to meta-regression analysis(1) and
41% in this individual-level analysis.
The PTE values we report here are high and they are of sim-
ilar magnitude or greater than PTE estimates based on analyses
of change in BMD and AR treatments, which vary from 4% to
72%.(7,9,12,31–35) The 95% CI associated with these PTE estimates
are wide and in some cases very wide, extending below 0 and
above 100%. Using similar methods as reported here, we are
currently conducting a PTE in this database that incorporates
both change in BTM and change in DXA BMD. It will be interest-
ing to see how the results compare with the results for BTMs
alone and whether the combination of BMD and BTM is even
better.
Why is there a stronger relationship between change in BTM
and reduction in vertebral fracture risk with AR compared with
effects on nonvertebral and hip fracture? The vertebra is rich in
cancellous bone and the impact of AR is to increase BMD and to
prevent the development of stress risers and plate perfora-
tion.(36) At a clinical level, it has been observed that a large
increase in bone remodeling is often associated with an
increase in vertebral fracture risk (but not always other frac-
tures). Such large increases in remodeling can occur during
the third trimester of pregnancy(37) and after stopping denosu-
mab therapy.(38)
Our study has several strengths. It is the first study to combine
randomized controlled trials to calculate PTE with improved pre-
cision. We have not found such combined studies in any other
disease area. We have used individual-level data, so this
approach is not dependent upon published analyses. We used
a novel imputation approach, which we applied to all data, con-
sistent fracture definition, and PTE methodology.(10) We have
reported 95% confidence intervals for PTE. We acknowledge that
we report multiple such intervals, so this should be taken into
account in interpretation.
Our study does have limitations. We were able to include
most but not all major AR RCTs. We did not include anabolic
treatment RCTs. We had a problem of significant missing data
with a requirement for imputation. We had no control over
the specific BTM assays or quality control. We chose to stan-
dardize our results using percent change rather than standard
deviation (SD) units or absolute units because the assays them-
selves were not standardized. Imputation of the expected
values of the BTMs, rather than random draws from their condi-
tional distribution, could increase apparent precision. The
results apply to groups rather than individuals; we plan to work
on threshold analyses in the future to address this. The results
apply to antiresorptive but not anabolic treatments. The results
are applicable to bisphosphonates and SERMs; it is uncertain if
and how they might be used for drugs with other mechanisms
of action such as anabolic drugs.
In summary, in this large pooled analysis of individual-level
data frommultiple osteoporosis treatment trials, we found that
a substantial part of the reduction in vertebral fracture risk
could be explained by the changes in several bone turnover
markers.
Fig 1. Relationship between reduction in bone turnover markers and
vertebral fracture risk. (A) Bone ALP; (B) PINP; (C) CTX.
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